Oxytocin's Peripheral Analgesic Effects Model to be Validated in Healthy Volunteers and Knee Arthritis Patients

Osteoarthritis (OA) is a debilitating joint disease characterized by chronic pain, inflammation, and cartilage degradation, significantly impacting quality of life. Current pain management strategies, including NSAIDs and opioids, often carry substantial side effects or risks, highlighting an urgent need for novel, non-addictive analgesics. Oxytocin, a neuropeptide traditionally known for its roles in social bonding and parturition, has also demonstrated analgesic properties, particularly through central mechanisms. However, its potential for direct peripheral pain relief, independent of central nervous system effects, remains less understood. This study aims to fill this critical gap by developing and validating a pharmacodynamic model for oxytocin's peripheral actions, potentially opening new avenues for targeted pain therapy.

This single-day, Phase 2 study recruited 25 participants, comprising healthy volunteers and individuals suffering from severe knee arthritis requiring joint replacement. Each participant underwent intravenous (IV) catheter placement, followed by an IV infusion of oxytocin at varying, targeted concentrations. The primary objective was to evaluate changes in peripheral pain perception. Researchers employed quantitative sensory testing, specifically applying a heat probe to the skin, heating it to 113 degrees Fahrenheit for 5 minutes. Participants then scored their experienced pain on a 0 to 10 numerical rating scale, allowing for the assessment of oxytocin's dose-dependent effects on pain thresholds and intensity at a peripheral site.

The provided abstract describes the study's design and objectives rather than its results. As such, no specific findings, statistical data, or quantitative outcomes regarding oxytocin's peripheral analgesic effects are available in this record. The study's primary goal was to validate a pharmacodynamic model for pain relief, which would typically involve analyzing dose-response relationships and changes in pain scores. Future publications from this completed trial (NCT05929339) are anticipated to detail how varying oxytocin concentrations impacted pain perception in both healthy and arthritic populations, potentially revealing significant shifts in pain thresholds or intensity.